Lumenis launched a field guide to help cataract and refractive surgeons unmask ocular surface disease that may contribute to the “unhappy 20/20 patient” and manage it throughout the surgical journey, the company said in a press release. "Preventing 20/Unhappy: A Field Guide for Cataract and Refractive Surgeons" was unveiled at the 2026 American Academy of Ophthalmology annual meeting in New Orleans.

According to Lumenis, the resource combines current research, clinical insights, and practical strategies to incorporate ocular surface care into existing workflows. The field guide is divided into 2 parts spanning clinical care and practice implementation. “The Read” centers on the clinical side, covering preoperative screening, matching treatment to the disease, patient conversations, and postoperative care. “The Rollout” focuses on implementation, including demonstrating the value of ocular surface care, assembling the right team, and gaining staff buy-in.

Drawing on insights from 5 cataract and refractive surgeons—Christopher Starr, MD, FACS; Preeya Gupta, MD; Brett Levinson, MD; ShareenGreenbaum, MD; and Eric Gershenbaum, MD—as well as findings from 6 studies, the guide also includes 6 tear-out tools designed for clinical use. In addition, the field guide also addresses what comes after ocular surface disease is detected, with guidance on treatment planning, matching treatment to disease severity, and determining when a patient is ready for surgery. Treatment options include OptiLIGHT, an intense pulsed light (IPL) device that is FDA-approved for dry eye management due to meibomian gland dysfunction.

1. PTs indicative of PDR: diabetic retinopathy (if LLT ‘proliferative diabetic retinopathy’), vitreous hemorrhage, iris neovascularization, retinal neovascularization, glaucoma (if LLT ‘neovascular glaucoma’), neovascularization